-
11.发明授权公开(公告)号：US07258985B2
公开(公告)日：2007-08-21
申请号：US09750424
申请日：2000-12-28
CPC分类号： C07K16/005 , A61K2039/505 , C07K16/00 , C07K16/14 , C07K2317/622 , C07K2317/80 , C07K2318/10 , C07K2319/00 , C12N15/1055 , C12N15/1093
摘要： A method for the isolation of CDRs in a defined framework that is stable and soluble in reducing environment is described as well as thus obtainable scFv. Starting from such scFv with defined framework a scFv library can be generated wherein the framework is conserved while at least one complementary determining region (CDR) is randomized. Such library, e.g. in yeast cells, is suitable for screening for antibody/CDR-interactions or for screening for antibodies.
-
公开(公告)号：US20130345292A1
公开(公告)日：2013-12-26
申请号：US13667723
申请日：2012-11-02
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622
摘要： The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerisation of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.
摘要翻译： 本发明公开了一种分离的抗体，其选择性地结合Abeta的C-末端部分并且是人源化的或完全人的。 本发明的抗体能够防止Aβ的低聚。 此外，诊断方法包括以下步骤：（i）标记抗体; （ii）向受试者鼻内或全身施用有效剂量的所述抗体; 并且（iii）公开了检测受试者体内部分标记的抗体的浓度和/或存在。
-
公开(公告)号：US08323647B2
公开(公告)日：2012-12-04
申请号：US12677732
申请日：2008-09-15
IPC分类号： A61K39/395 , C07K16/18 , C12P21/08
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622
摘要： The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerization of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.
摘要翻译： 本发明公开了一种分离的抗体，其选择性地结合Abeta的C-末端部分并且是人源化的或完全人的。 本发明的抗体能够防止Aβ的低聚。 此外，诊断方法包括以下步骤：（i）标记抗体; （ii）向受试者鼻内或全身施用有效剂量的所述抗体; 并且（iii）公开了检测受试者体内部分标记的抗体的浓度和/或存在。
-
公开(公告)号：US20120064077A1
公开(公告)日：2012-03-15
申请号：US13245420
申请日：2011-09-26
IPC分类号： A61K39/395 , C12N15/63 , C12N1/21 , C12N1/19 , C12N5/10 , G01N33/566 , C07K16/24 , A61P19/02 , A61P27/02 , A61P1/00 , A61P29/00 , C12N15/13 , C12P21/02
CPC分类号： C07K16/241 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/522 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNFα, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNFα, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNFα-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
摘要翻译： 本发明涉及特别稳定和可溶的scFv抗体和对TNFα特异性的Fab片段，其包含针对TNFα的稳定性，溶解性，体外和体内结合而优化的特异性轻链和重链序列以及低免疫原性。 所述抗体被设计用于诊断和/或治疗TNFα相关疾病。 还公开了用于表达本发明的重组抗体的核酸，载体和宿主细胞，用于分离它们的方法和所述抗体在医学中的用途。
-
15.发明授权Method for treating glioblastoma using antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK 有权使用结合受体酪氨酸激酶ALK的细胞外结构域的抗体治疗胶质母细胞瘤的方法公开(公告)号：US08945563B2
公开(公告)日：2015-02-03
申请号：US13017925
申请日：2011-01-31
IPC分类号： A61K39/395 , C07K16/28 , C07K16/30 , A61K39/00
CPC分类号： C12N9/12 , A61K39/00 , A61K2039/505 , C07K16/2896 , C07K16/30 , C07K2317/34 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/92 , C12Y207/10001
摘要： The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma.
摘要翻译： 本发明涉及对人ALK（间变型淋巴瘤激酶）特异性的抗体，特别是scFv，编码它的核酸序列，其生产及其作为药物或用于诊断目的的用途。 所述抗体适用于局部治疗肿瘤，特别是成胶质细胞瘤。
-
公开(公告)号：US20090311251A1
公开(公告)日：2009-12-17
申请号：US12307875
申请日：2007-07-10
IPC分类号： A61K39/395 , G01N33/53 , C07K16/00
CPC分类号： C07K16/18 , A61K39/39591 , A61K2039/505 , A61K2039/54 , C07K16/22 , C07K16/241 , C07K2317/24 , C07K2317/622
摘要： scFv antibodies which specifically bind selected antigens and are obtainable by a method comprising (i) selecting from a pool of soluble and stable antibody frameworks a soluble and stable framework matching best the framework of a non-human antibody against the antigen with a certain binding specificity, (ii) either providing said soluble and stable framework with CDRs that bind specifically to said antigen, or mutating the framework of said non-human antibody towards the sequence of said soluble and stable framework, to generate scFv antibodies, (iii) testing the generated antibody for solubility and stability, and testing the generated antibody for antigen binding, and (iv) selecting an scFV that is soluble, stable and binds to the antigen specifically. Also provided are pharmaceutical compositions comprising said scFv antibody, methods of treatment and diagnosis for diseases related to over expression of antigens that are specifically bound by said antibody.
摘要翻译： scFv抗体，其特异性结合所选择的抗原，并且可通过以下方法获得：（i）从可溶性和稳定的抗体框架库中选择可溶性和稳定的框架，以最佳匹配抗人抗体的框架与一定的结合特异性 提供与所述抗原特异性结合的CDR提供所述可溶性和稳定的框架，或者将所述非人抗体的框架朝向所述可溶性和稳定框架的序列突变以产生scFv抗体，（iii）测试 产生抗体的溶解度和稳定性，并测试所产生的抗体的抗原结合，和（iv）选择可溶性，稳定并特异性结合抗原的scFV。 还提供了包含所述scFv抗体的药物组合物，与由所述抗体特异性结合的抗原过度表达相关疾病的治疗和诊断方法。
-
公开(公告)号：US20090263382A1
公开(公告)日：2009-10-22
申请号：US11916793
申请日：2006-06-06
IPC分类号： A61K39/395 , C12P21/08 , C12N5/06 , C12N5/04 , C12N1/21 , C12N1/19 , C12N15/00 , C07K16/18 , C12N15/11
CPC分类号： C07K16/241 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/522 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNFα, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNFα, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNFα-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
摘要翻译： 本发明涉及特别稳定和可溶的scFv抗体和对TNFα特异性的Fab片段，其包含针对TNFalpha的稳定性，溶解性，体外和体内结合而优化的特异性轻链和重链序列以及低免疫原性。 所述抗体被设计用于诊断和/或治疗TNFα相关疾病。 还公开了用于表达本发明的重组抗体的核酸，载体和宿主细胞，用于分离它们的方法和所述抗体在医学中的用途。
-
18.发明申请Intrabodies with defined framework that is stable in a reducing environment and applications thereof 审中-公开具有在还原环境中稳定的具有框架的体内抗体及其应用公开(公告)号：US20080233110A1
公开(公告)日：2008-09-25
申请号：US11894097
申请日：2007-08-20
IPC分类号： A61K39/395 , C07K16/00 , C40B30/06 , C40B50/00 , C40B40/10
CPC分类号： C07K16/005 , A61K2039/505 , C07K16/00 , C07K16/14 , C07K2317/622 , C07K2317/80 , C07K2318/10 , C07K2319/00 , C12N15/1055 , C12N15/1093
摘要： A method for the isolation of CDRs in a defined framework that is stable and soluble in reducing environment is described as well as thus obtainable scFv. Starting from such scFv with defined framework a scFv library can be generated wherein the framework is conserved while at least one complementary determining region (CDR) is randomized. Such library, e.g. in yeast cells, is suitable for screening for antibody/CDR-interactions or for screening for antibodies.
摘要翻译： 描述了在限定的框架中分离CDR的方法，其稳定和可溶于还原环境，以及由此获得的scFv。 从具有定义框架的这种scFv开始，可以生成scFv文库，其中框架是保守的，而至少一个互补决定区（CDR）是随机的。 这样的文库，例如 在酵母细胞中，适用于筛选抗体/ CDR相互作用或筛选抗体。
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.017 秒)
